Riluzole tablet ( DrugBank: Riluzole )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
2	筋萎縮性側索硬化症	2

2. 筋萎縮性側索硬化症

---

臨床試験数 : 624 /  薬物数 : 611 - (DrugBank : 160) / 標的遺伝子数 : 172 - 標的パスウェイ数 : 225

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2100044085	2021-03-01	2021-03-09	A multicenter, randomized, double-blind, positive drug parallel controlled clinical trial to evaluate the efficacy and safety of Huolingshengji Keli granules for the treatment of amyotrophic lateral sclerosis (ALS).	A multicenter, randomized, double-blind, positive drug parallel controlled clinical trial to evaluate the efficacy and safety of Huolingshengji Keli granules for the treatment of amyotrophic lateral sclerosis (ALS).	Amyotrophic lateral sclerosis	experimental group:Huoling Shengji Keli granules 1 bag + riluzole tablets simulant 1 tablet each time, Bid, oral;control group:Huoling Shengji Keli granules simulant 1 bag + riluzole tablets 1 tablet each time, Bid, oral;	Peking University Third Hospital	NULL	Recruiting	45	70	Both	experimental group:72;control group:72;	Phase 2	China
2	NCT04950933 (ClinicalTrials.gov)	June 1, 2020	27/6/2021	The Treatment of Amyotrophic Lateral Sclerosis With Huollingshengji Granules	A Multi-center, Randomized, Double-blind, Positives Parallel Controlled, Phase ? Clinical Trial to Evaluate the Efficacy and Safety of Huollingshengji Granules in the Treatment of Amyotrophic Lateral Sclerosis (Spleen qi Deficiency, Kidney Yang Deficiency Syndrome)	Amyotrophic Lateral Sclerosis	Drug: Huolingshengji Granules;Drug: Riluzole tablet	Peking University Third Hospital	The Second Hospital of Hebei Medical University	Recruiting	45 Years	70 Years	All	144	Phase 2/Phase 3	China